Elanco Announces European Commission Approval of Pending Acquisition of Bayer Animal Health
- Divestiture of the worldwide rights for Osurnia?, a treatment for otitis externa in dogs, being sold to Dechra Pharmaceuticals PLC (LON: DPH)
- Divestiture of the worldwide rights for Vecoxan?, used for prevention and treatment of coccidiosis in calves and lambs being sold to Merck Animal Health (also known as MSD Animal Health).
- Divestiture of European Economic Area and UK rights to the Drontal? and Profender? product families and related pipeline assets from Bayer Animal Health being sold to Vetoquinol SA (EURONEXT: VETO), a French pharmaceutical company. These products are broad-spectrum de-wormers for dogs and cats.